AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22451195
Drug: FOLFOX/FOLFIRI sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX/FOLFIRI sequential chemotherapy
Trial: 19035721
Drug: Intravenous nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nicardipine (5-15 mg/hour)
Trial: 10713577
Drug: Acetylcholinesterase inhibitors
RxNorm normalized name: acetylcholinesterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcholinesterase inhibitors (ChIs)
Trial: 9239913
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oestradiol valerate and 2.5 mg medroxyprogesterone acetate
Trial: 30291370
Drug: Topical atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical atorvastatin 1%
Trial: 27617502
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate (27 mg per day for 8 weeks)
Trial: 27617502
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (320 mg per day for 8 weeks)
Trial: 27617502
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 8 weeks)
Trial: 19147689
Drug: Concomitant anthracycline
RxNorm normalized name: methacycline
DrugBank: Metacycline (DB00931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant anthracycline therapy
Trial: 16332430
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) as an add-on treatment
Trial: 10365896
Drug: TUBT (tablet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TUBT (tablet-based 13C urea breath test)
Trial: 7578166
Drug: simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 10 mg daily
Trial: 2194314
Drug: gemfibrozil 600
RxNorm normalized name: gemfibrozil 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemfibrozil 600 mg twice daily
Trial: 7578166
Drug: cholestyramine 4
RxNorm normalized name: CHOLESTYRAMINE 4GM CHEW BAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cholestyramine 4 gm twice daily
Trial: 2272022
Drug: Apomorphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine (10 micrograms/kg subcutaneously with oral domperidone 10 mg)
Trial: 2272022
Drug: Oral sultopride
RxNorm normalized name: Sultopride
DrugBank: Sultopride (DB13273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sultopride (50 mg)
Trial: 23972505
Drug: Topical 0.2%
RxNorm normalized name: coal tar topical 0.2% topical soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.2% nitroglycerin ointment
Trial: 22357861
Drug: Test and
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test and mask stimuli with distinct temporal frequencies; specific details on dosage and duration not applicable.
Trial: 22357861
Drug: Test and
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test and mask stimuli with equal contrast; specific details on dosage and duration not applicable.
Trial: 22357861
Drug: Divisive gain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divisive gain control models with 30 ms integration time; specific details on dosage and duration not applicable.
Trial: 22357861
Drug: Contrast normalization;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast normalization; specific details on dosage and duration not applicable.
Trial: 18060342
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no infliximab therapy)
Trial: 10624430
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen (g. cyclopentolate 1% stat. and oc. chloramphenicol q.d.s. for 5 days)
Trial: 10624430
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen followed by additional nightly ointment (Lacrilube) for 2 months
Trial: 2188826
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg daily (n = 68)
Trial: 2188826
Drug: Sustained-release nifedipine
RxNorm normalized name: nifedipine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release nifedipine 20 mg twice daily (n = 68)
Trial: 7198465
Drug: plafibride (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: plafibride (1200 mg/d for 15 days)
Trial: 25907488
Drug: Xinkeshu (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinkeshu (12 capsules/d) on top of standard therapy
Trial: 25907488
Drug: Placebo on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo on top of standard therapy
Trial: 21836413
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with half-dose verteporfin
Trial: 19169191
Drug: Pharmacotherapy (e.g.,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (e.g., selective serotonin reuptake inhibitors)
Trial: 19169191
Drug: Consensus guidelines
RxNorm normalized name: Consensi
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consensus guidelines on pharmacotherapy for PTSD
Trial: 14755505
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC)
Trial: 11090571
Drug: CC (2
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CC (2 g/kg body wt of CHO in a 25.7% CHO beverage 30 min before and 2 g/kg of CHO in a 6.4% CHO solution throughout SS)
Trial: 11090571
Drug: PC (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PC (placebo 30 min before and 2 g/kg body wt of CHO in a 6.4% CHO solution throughout SS)
Trial: 11090571
Drug: CP (2
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CP (2 g/kg body wt of CHO in a 25.7% CHO beverage 30 min before and placebo throughout SS)
Trial: 9069692
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care (40-hour training program)
Trial: 8417381
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy with fluorouracil
Trial: 8417381
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy without fluorouracil
Trial: 8417381
Drug: Smoking during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking during radiation therapy
Trial: 3770045
Drug: Corynebacterium parvum
RxNorm normalized name: Corynebacterium parvum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corynebacterium parvum (2 mg/m2) every 3 weeks for a maximum of eight courses followed by DTIC (250 mg/m2 i.v. daily X 5) and Actinomycin D (1.5 mg/m2 on Day 1)
Trial: 3770045
Drug: DTIC (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC (250 mg/m2 i.v. daily X 5) and Actinomycin D (1.5 mg/m2 on Day 1)
Trial: 3770045
Drug: Corynebacterium parvum
RxNorm normalized name: Corynebacterium parvum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corynebacterium parvum followed by chemotherapy
Trial: 31314785
Drug: Concurrent-100% feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent-100% feedback
Trial: 31314785
Drug: Concurrent-50% feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent-50% feedback
Trial: 20632322
Drug: Metronidazole 10
RxNorm normalized name: metronidazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 10 per cent ointment, 0.7 g applied perianally three times daily
Trial: 20632322
Drug: Metronidazole 10
RxNorm normalized name: metronidazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 10 per cent ointment
Trial: 15978101
Drug: S18886 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S18886 1 mg
Trial: 15978101
Drug: S18886 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S18886 2.5 mg
Trial: 15978101
Drug: S18886 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S18886 5 mg
Trial: 15978101
Drug: S18886 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S18886 10 mg
Trial: 15978101
Drug: S18886 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S18886 30 mg
Trial: 12814908
Drug: Thiamine-enriched beer
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamine-enriched beer (10 mg of thiamine)
Trial: 12814908
Drug: Normal beer
RxNorm normalized name: BEER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal beer (0 mg of thiamine)
Trial: 10997482
Drug: SCE (synthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCE (synthetic conjugated estrogens, A) 0.3 mg, 0.625 mg, or 1.25 mg per day
Trial: 1448777
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose epinephrine infusion
Trial: 30629183
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement therapy (250 mg intramuscular injections every 2 weeks for 22 weeks)
Trial: 21427372
Drug: Hydrocortisone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (200 mg/d for 5 days, followed by 100 mg on day 6 and 50 mg on day 7)
Trial: 11158489
Drug: Point-of-care evidence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point-of-care evidence delivery regarding the use and duration of antibiotics for otitis media.
Trial: 2403603
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sulfamethoxazole and trimethoprim (1600/320 mg) plus loperamide hydrochloride (4 mg loading dose, then 2 mg after each loose stool)
Trial: 2403603
Drug: Sulfamethoxazole and
RxNorm normalized name: sulfamethoxazole and trimethoprim
DrugBank: Sulfamethoxazole (DB01015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfamethoxazole and trimethoprim (800/160 mg orally twice daily)
Trial: 2403603
Drug: Loperamide hydrochloride
RxNorm normalized name: Loperamide Hydrochloride
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loperamide hydrochloride (4 mg loading dose, then 2 mg after each loose stool)
Trial: 30677766
Drug: MP-AzeFlu (137/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MP-AzeFlu (137/50 μg AZE/FP per spray)
Trial: 30677766
Drug: AZE (137
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZE (137 μg/spray)
Trial: 25462393
Drug: Short-term psychotherapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term psychotherapy (Solution-Focused Therapy, SFT, n=97)
Trial: 25462393
Drug: Short-term therapies
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term therapies (SFT and SPP)
Trial: 23963054
Drug: Oral α‐methylparatyrosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral α‐methylparatyrosine (AMPT)
Trial: 7890905
Drug: Colchicine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1 mg orally daily)
Trial: 3224534
Drug: Thiopental (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (loading dose of 15 mg/kg over 30 min followed by constant infusion)
Trial: 27027616
Drug: N-acetylcysteine (N-AC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (N-AC) 70 mg kg(‐1)
Trial: 24632280
Drug: FIRM-blinded therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIRM-blinded therapy
Trial: 23400715
Drug: Sifalimumab (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sifalimumab (0.3, 1.0, 3.0, or 10.0 mg/kg)
Trial: 22131734
Drug: Pradhamana Nasya
RxNorm normalized name: Hyaluronic acid (NASHA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradhamana Nasya followed by oral Trayodashanga Kwatha with Madhu (Group C)
Trial: 12851520
Drug: Antihypertensive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive agents (beta-blocker, non-beta-blocker, or beta-blocker plus non-beta-blocker)
Trial: 9231864
Drug: Opioid drug
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid drug via patient-controlled analgesia (PCA) systems for 7 days or more
Trial: 7956549
Drug: PG05 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PG05 0.25 mg
Trial: 7956549
Drug: ONO-802 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-802 0.125 mg
Trial: 3310925
Drug: Nonathymulin 5
RxNorm normalized name: NONATHYMULIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonathymulin 5 mg/day
Trial: 23362148
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic fields (PEMFs) treatment
Trial: 17348883
Drug: Standard cylindrical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cylindrical implants
Trial: 30902603
Drug: Tapered implants
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tapered implants
Trial: 22672713
Drug: Both implant
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both implant designs
Trial: 5109411
Drug: Intrathecal chemotherapy
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal chemotherapy with methotrexate
Trial: 5109411
Drug: Intrathecal chemotherapy
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal chemotherapy with cytosine arabinoside
Trial: 5109411
Drug: Prophylactic intrathecal
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic intrathecal chemotherapy (control group)
Trial: 28164731
Drug: PEC I
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEC I (consume 50 mL of PEC/day)
Trial: 28164731
Drug: PEC II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEC II (consume 100 mL of PEC/day)
Trial: 28164731
Drug: Placebo (consume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (consume 50 mL of simulated prune drink)
Trial: 25740672
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol 5 mg/mL solution applied twice daily for an average of 4.0 ± 1.1 months
Trial: 25740672
Drug: Combined sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined sequential pulsed dye and Nd:YAG laser treatment for an average of 5.5 ± 0.9 months
Trial: 17076630
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of timolol and dorzolamide
Trial: 11696618
Drug: Standard-fractionated radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-fractionated radiotherapy (60 Gy/30 fractions/6 weeks) with concurrent cisplatin (80 mg/m² on day 1) and vindesine (3 mg/m² on days 1 and 8 every 4 weeks)
Trial: 11696618
Drug: Accelerated-hyperfractionated radiotherapy
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated-hyperfractionated radiotherapy (54 Gy/36 fractions/3.6 weeks) with concurrent cisplatin (80 mg/m² on day 1) and vindesine (3 mg/m² on days 1 and 8 every 4 weeks)
Trial: 9043729
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg glycopyrrolate im
Trial: 9043729
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg hyoscine hydrobromide po
Trial: 9043729
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg hyoscine hydrobromide im
Trial: 2407084
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg orally 3 times daily (group 1, n = 115)
Trial: 2407084
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg orally 3 times daily plus dipyridamole 75 mg orally 3 times daily (group 2, n = 117)
Trial: 2407084
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg orally 3 times daily (group 1)
Trial: 2407084
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg orally 3 times daily plus dipyridamole 75 mg orally 3 times daily (group 2)
Trial: 7002183
Drug: Aspirin (250,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (250, 500, and 1000 mg)
Trial: 7002183
Drug: New formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New formulations of Optalidon (aminopyrine replaced by propyphenazone)
Trial: 7002183
Drug: New formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New formulations of Tonopan (aminopyrine replaced by propyphenazone)
Trial: 7002183
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aminopyrine, caffeine, and butalbarbital (Optalidon)
Trial: 7002183
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aminopyrine, caffeine, butalbarbital, and dihydroergotamine (Tonopan)
Trial: 16126743
Drug: Usual daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual daily activities
Trial: 31724026
Drug: Fixed-Duration Chemotherapy-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-Duration Chemotherapy-Free Treatment
Trial: 28545978
Drug: Benralizumab 30
RxNorm normalized name: benralizumab 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab 30 mg injections every 4 weeks for 12 weeks
Trial: 20102872
Drug: Glycemia levels
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycemia levels categorized as < or = 100 mg/dL (5.5 mmol/L)
Trial: 1611640
Drug: Diltiazem hydrochloride
RxNorm normalized name: Diltiazem Hydrochloride
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem hydrochloride 120 mg
Trial: 1611640
Drug: Diltiazem hydrochloride
RxNorm normalized name: Diltiazem Hydrochloride
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem hydrochloride 240 mg
Trial: 1611640
Drug: Diltiazem hydrochloride
RxNorm normalized name: Diltiazem Hydrochloride
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem hydrochloride 360 mg
Trial: 1611640
Drug: Diltiazem hydrochloride
RxNorm normalized name: Diltiazem Hydrochloride
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem hydrochloride 480 mg
Trial: 30584293
Drug: IND/MF (QMF149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IND/MF (QMF149) 150/160 µg once daily
Trial: 30584293
Drug: Sal/Flu (50/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sal/Flu (50/500 µg twice daily)
Trial: 11276406
Drug: Antidepressant treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatments (specifics not provided)
Trial: 11276406
Drug: Nonexperimental evidence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonexperimental evidence of antidepressant use (specifics not provided)
Trial: 11276406
Drug: Comprehensive model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive model for assessing antidepressant use in youths
Trial: 8385750
Drug: Natural conjugates
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Natural conjugates oestrogen (0.625 mg per diem per os) plus MAP (10 mg per diem per os) for 12 days a month
Trial: 29117990
Drug: Midostaurin (PKC412)
DrugBank: Midostaurin (DB06595)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Midostaurin (PKC412) administered daily for 4 days
Trial: 25274978
Drug: 9-valent HPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent HPV vaccine (HPV6/11/16/18/31/33/45/52/58)
Trial: 24423823
Drug: Chemotherapy (cisplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cisplatin, gemcitabine, paclitaxel, and pemetrexed) under the guidance of molecular markers
Trial: 24423823
Drug: Vinorelbine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25 mg/m(2) days 1 and 8 with 21 days as a cycle
Trial: 18849230
Drug: Internal thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal thoracic artery preparation with intact pleura (Group 1)
Trial: 16449899
Drug: Brace treatment
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brace treatment (BT)
Trial: 11042989
Drug: 15 percent
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 percent CP whitening agent